CA-NEXON-AMERICA
MapleStory 2 , the all new MMORPG from the MapleStory franchise with over 14 million players around the world, is available globally today via Nexon Launcher and Steam . The game provides a robust set of character options, an innovative progression and growth system, and world-building tools, redefining the MMORPG genre by giving players the ability to customize everything.
Coming over from the beta and Head Start, the game includes the classes of Archer, Assassin, Berserker, Heavy Gunner, Knight, Priest, Thief, Wizard, and is also introducing its impressive new Runeblade class. This new class is a magical swordsman that infuses his swords with the elements for ultimate power and uses a special 2-handed bladed weapon that uses up both weapon slots.
For the official launch, MapleStory 2 delivers incredible content updates that have improved gameplay quality such as:
- Lv. cap increase from 50 to 60
- The gorgeous Karkar Island
- Lv. 51 – 60 fields in Maple World / Land of Darkness
- 8 Normal Adventure Dungeons
- 4 Hard Adventure Dungeons
- 2 Sets of Epic Gear
MapleStory 2 has limited time launch events including a Daily Reward Event running from October 10 to November 8. By logging in daily, players will receive rewards including Maple Coins, Cosmetics Vouchers, Elixirs, and more.
In the game you can:
- Claim Your Destiny as an Epic Hero - Players will find colorful 3D landscapes to explore, loads of new and familiar enemies to vanquish, and exciting bosses to battle.
- Build Your Dream World - MapleStory 2 redefines the role-playing game genre with a complete commitment to creativity, arming players with a robust set of character and world-building tools that allow them to express themselves unlike ever before.
- Explore a New Dimension of MapleStory - Maplers can enter a whole new dimension of Maple World and encounter vivid 3D landscapes, a multitude of special events, exciting minigames, and enemies both familiar and completely original.
From October 10 through October 21, players can also receive a Mint Body Pillow by following MapleStory 2 on Twitter or Facebook and retweeting or sharing the Official Launch Gameplay video. Forty winners will be selected.
Also, from October 18 through November 8, MapleStory 2 will host various Halloween events, themed dungeons, and fun quests. Players who defeat the Halloween Messenger can collect Pumpkin Coins and exchange for special Halloween themed items. Lv. 10+ characters, can also obtain a “Pumpky Nest” item in their house by completing quests for furnishing items. Players can claim rewards including the Bouncy Pumpky Mount, Little Pumpky Pet, and Perched Pumpky.
To learn more about MapleStory 2 , please visit http://maplestory2.nexon.net/en .
Assets : MapleStory 2
Trailers:
MapleStory 2
Official Launch
Trailer: https://youtu.be/whVoKizV0Mg
MapleStory
2
Runeblade Trailer: https://youtu.be/a4vzKedyhk4
Social Media : Twitch / Facebook / Twitter / YouTube / Instagram
About MapleStory 2
http://maplestory2.nexon.net/en
Set
in a colorful 3D block universe, MapleStory 2
is one of
the most creative and customizable MMORPGs available on the market
today. MapleStory 2
implements a robust set of character
options, a brand new progression and growth system, and world-building
tools, redefining the MMORPG genre by giving players the ability to
customize everything.
About Nexon America Inc.
http://www.nexon.net
Nexon
America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a
global leader in online games, with more than 100 live games operated
across more than 190 countries. Nexon pioneered micro-transactions and
the free-to-play business model, and is widely credited with unmatched
global expertise in sophisticated live game operations, nurturing player
communities, and for sustaining titles for years, even decades. Founded
in Korea in 1994, the company is now headquartered in Japan and listed
on the Tokyo Stock Exchange. In 2017, Nexon was placed on the Nikkei
Stock Index 300.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181010005821/en/
Contact:
B/HI for Nexon Wahid Lodin wahid_lodin@bhimpact.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release
Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom